MOLECULAR IMAGING AND THERANOSTICS OF NEUROENDOCRINE TUMORS: THE ROLE OF SSTR-PET, RADIOPHARMACEUTICALS, AND RADIOMICS IN PERSONALIZED DIAGNOSTICS

Abstract

The review presents modern approaches to the molecular imaging of neuroendocrine tumors based on the use of somatostatin-receptor radiopharmaceuticals, hybrid PET technologies and radiomics methods. The diagnostic and prognostic possibilities of SSTR-PET/CT, FDG-PET are considered/CT and PET/MRI in the assessment of the biological behavior of NEO of various gradations. Special attention is paid to the molecular mechanisms of somatostatin receptor expression, the use of 68Ga and 64Cu-labeled radioligands, as well as the integration of AI algorithms and radiomic features into personalized theranostics. Modern biomarkers of PRRT efficacy, including NETest and transcriptome panels, have been analyzed. The presented data demonstrate the formation of a new paradigm for the molecular diagnosis of NEO, based on a combination of functional imaging and biological characteristics of the tumor.